The US Food and Drug Administration (FDA) issued a drug safety communication on April 26, 2013, alerting the medical community that ezogabine (Potiga™; GlaxoSmithKline, Research Triangle Park, North Carolina), one of the newest antiepileptic drugs, may cause blue-gray skin discoloration and retinal pigment changes.
Ezogabine
Ezogabine, formerly known as retigabine, received FDA approval as Potiga for adjunctive treatment of partial-onset seizures in adults on June 10, 2011. Ezogabine is a positive allosteric modulator of KCNQ2-5 potassium channels that inhibits high-frequency action potential firing, a unique mechanism of action for an antiepileptic drug.[2] Ezogabine was co-developed by GlaxoSmithKline and Valeant Pharmaceuticals and marketed as Trobalt® in the European Union. An article[3]about ezogabine that included a summary of 2 phase 3 clinical trials appeared in this column shortly after the drug received FDA approval
(fonts: medscape)
Nessun commento:
Posta un commento